Johnson & Johnson (NYSE:JNJ) Shares Sold by Violich Capital Management Inc.

Violich Capital Management Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,734 shares of the company’s stock after selling 7,640 shares during the quarter. Johnson & Johnson makes up 3.3% of Violich Capital Management Inc.’s holdings, making the stock its 7th biggest position. Violich Capital Management Inc.’s holdings in Johnson & Johnson were worth $15,891,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Winslow Evans & Crocker Inc. increased its position in shares of Johnson & Johnson by 0.3% in the second quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after purchasing an additional 69 shares during the period. Lathrop Investment Management Corp grew its position in Johnson & Johnson by 1.4% in the second quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock valued at $689,000 after acquiring an additional 69 shares during the last quarter. Reik & CO. LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock valued at $2,493,000 after acquiring an additional 70 shares during the last quarter. Old North State Trust LLC grew its position in Johnson & Johnson by 0.5% in the second quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock valued at $1,922,000 after acquiring an additional 71 shares during the last quarter. Finally, Delta Investment Management LLC grew its position in Johnson & Johnson by 1.0% in the second quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock valued at $1,041,000 after acquiring an additional 71 shares during the last quarter. 67.44% of the stock is owned by institutional investors and hedge funds.

A number of research firms have issued reports on JNJ. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Independent Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $161.00 to $164.00 in a research report on Monday, July 20th. Raymond James lifted their target price on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Citigroup boosted their price target on Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Finally, SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $164.93.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.

Shares of Johnson & Johnson stock traded up $0.33 during midday trading on Wednesday, reaching $144.88. The company had a trading volume of 47,139 shares, compared to its average volume of 8,235,604. The stock has a fifty day moving average price of $148.06 and a 200 day moving average price of $146.95. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The firm has a market cap of $380.57 billion, a PE ratio of 22.73, a P/E/G ratio of 3.23 and a beta of 0.68. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 35.10% and a net margin of 21.01%. The firm had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. During the same period in the previous year, the firm earned $2.12 earnings per share. The company’s revenue was up 1.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 7.99 EPS for the current year.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: Stock Symbols Definition, Examples, Lookup

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.